Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Radford

Showing results (51-60 of 110) with videos related to

Pageof 11
Sort By:
British Journal of Haematology|December 2, 2017
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphomaLuca Arcaini, Thierry Lamy, Jan Walewski, et al.
Leukemia & Lymphoma|February 9, 2023
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphomaHoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, et al.
British Journal of Haematology|September 22, 2016
Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphomaScott D Ramsey, Auayporn Nademanee, Tamas Masszi, et al.
Expert Review of Anticancer Therapy|February 1, 2023
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphomaM Lia Palomba, Paola Ghione, Anik R Patel, et al.
British Journal of Haematology|January 4, 2014
Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)Carlo Messina, Andrés J M Ferreri, Silvia Govi, et al.
Blood|November 19, 2020
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphomaMehdi Hamadani, John Radford, Carmelo Carlo-Stella, et al.
The Lancet. Haematology|May 28, 2021
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion studyMehdi Hamadani, Graham P Collins, Paolo F Caimi, et al.
British Journal of Haematology|September 14, 2020
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)Adam Gibb, Sarah J Pirrie, Kim Linton, et al.
Haematologica|August 30, 2023
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 studyPaolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, et al.
Haematologica|October 20, 2022
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 studyPaola Ghione, M Lia Palomba, Hervé Ghesquieres, et al.
Pageof 11

Showing results (51-60 of 110) with videos related to

Sort By:
Pageof 11
British Journal of Haematology|December 2, 2017
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphomaLuca Arcaini, Thierry Lamy, Jan Walewski, et al.
Leukemia & Lymphoma|February 9, 2023
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphomaHoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, et al.
British Journal of Haematology|September 22, 2016
Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphomaScott D Ramsey, Auayporn Nademanee, Tamas Masszi, et al.
Expert Review of Anticancer Therapy|February 1, 2023
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphomaM Lia Palomba, Paola Ghione, Anik R Patel, et al.
British Journal of Haematology|January 4, 2014
Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)Carlo Messina, Andrés J M Ferreri, Silvia Govi, et al.
Blood|November 19, 2020
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphomaMehdi Hamadani, John Radford, Carmelo Carlo-Stella, et al.
The Lancet. Haematology|May 28, 2021
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion studyMehdi Hamadani, Graham P Collins, Paolo F Caimi, et al.
British Journal of Haematology|September 14, 2020
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)Adam Gibb, Sarah J Pirrie, Kim Linton, et al.
Haematologica|August 30, 2023
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 studyPaolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, et al.
Haematologica|October 20, 2022
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 studyPaola Ghione, M Lia Palomba, Hervé Ghesquieres, et al.
Pageof 11